BiotechTubeBiotechTube
Home/Regeneron Pharmaceuticals/Daniel Van Plew
DV

Daniel Van Plew

Executive Vice President, General Counsel

Regeneron Pharmaceuticals

Therapeutic Areas

OphthalmologyImmunologyOncologyCardiovascularInfectious Diseases

Regeneron Pharmaceuticals Pipeline

DrugIndicationPhase
EYLEA (aflibercept)Wet AMD, diabetic macular edema, retinal vein occlusionApproved
Dupixent (dupilumab)Atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposisApproved
Libtayo (cemiplimab)Cutaneous squamous cell carcinoma, basal cell carcinoma, NSCLCApproved
Praluent (alirocumab)High cholesterolApproved
Kevzara (sarilumab)Rheumatoid arthritisApproved
Evkeeza (evinacumab)Homozygous familial hypercholesterolemiaApproved
EYLEA HDWet AMD, diabetic macular edemaPhase 3
DupixentCOPDPhase 3

Leadership Team at Regeneron Pharmaceuticals

LS
Leonard Schleifer
Co-Founder, President and Chief Executive Officer
GY
George Yancopoulos
Co-Founder, President and Chief Scientific Officer
RL
Robert Landry
Executive Vice President and Chief Financial Officer
MM
Marion McCourt
Executive Vice President, Commercial
IL
Israel Lowy
Executive Vice President, Chief Medical Officer
CF
Christopher Fenimore
Vice President, Investor Relations
RC
Ryan Crowe
Executive Vice President, Chief Business Officer
View full Regeneron Pharmaceuticals profile